Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
100%
Overall Survival
43%
Cohort Analysis
36%
Multiple Myeloma
35%
Diseases
28%
Malignant Neoplasm
27%
Progression Free Survival
21%
Acute Myeloid Leukemia
21%
B Cell
20%
Neoplasm
19%
Venous Thromboembolism
19%
Positron Emission Tomography-Computed Tomography
19%
Hazard Ratio
18%
Rituximab
18%
Myeloma
17%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
15%
Hodgkin's Lymphoma
15%
Drug Megadose
13%
Follicular Lymphoma
12%
International Prognostic Index
12%
Non-Hodgkin Lymphoma
12%
Diagnosis
11%
Radiation Therapy
11%
Clinical Trial
11%
Biological Marker
11%
Autologous Stem Cell Transplantation
10%
CHOP
10%
Hematological Cancer
10%
Melphalan
9%
Central Nervous System
8%
Prognostic Factor
8%
B-Cell Chronic Lymphocytic Leukemia
8%
Cohort Effect
8%
Personalized Medicine
8%
Thrombosis
8%
Gene Expression Profiling
7%
Non Small Cell Lung Cancer
7%
Minimal Residual Disease
7%
Positron Emission Tomography
7%
microRNA
7%
Cancer
7%
Myelodysplastic Syndrome
7%
B-Cell Lymphoma
7%
Systematic Review
7%
Oncology
6%
Peripheral T-Cell Lymphoma
6%
Fluorodeoxyglucose F 18
6%
Positron Emission Tomography
6%
Infection
6%
Proportional Hazards Model
6%
Biopsy
6%
Vincristine
6%
Population
6%
Symptom
6%
Prevalence
6%
Monoclonal Gammopathy of Undetermined Significance
5%
Doxorubicin
5%
Cyclophosphamide
5%
Bone Marrow Biopsy
5%
Myeloproliferative Neoplasm
5%
Immunotherapy
5%
Transplantation
5%
Prednisone
5%
Low Drug Dose
5%
Targeted Therapy
5%
Keyphrases
National Cohort Study
11%
Diffuse Large B-cell Lymphoma (DLBCL)
8%
Lymphoma
7%
Lymphoma Patients
6%
Venous Thromboembolism
6%
Overall Survival
5%
Denmark
5%
Multiple Myeloma
5%
Confidence Interval
5%